Zonisamide and renal calculi in patients with epilepsy: how big an issue?

References

• Amato M, Lusini ML, Nelli F. Epidemiology of nephrolithiasis today. Urol Int 2004;72(Suppl 1):1–5
   Google Scholar
• Wasserstein AG. Nephrolithiasis: acute management and prevention. Dis Mon 1998;44:196–213
   PubMed Web of Science ®Google Scholar
• Ramello A, Vitale C, Marangella M. Epidemiology of nephrolithiasis. J Nephrol 2000;13(Suppl 3):S45–S50
   PubMedGoogle Scholar
• Pak CYC. Kidney stones. Lancet 1998;351:1797–801
   PubMed Web of Science ®Google Scholar
• Stametalou KK, Frances ME, Jones CA, et al. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 2003;63:1817–23
   PubMed Web of Science ®Google Scholar
• Abdel Goad EH, Bereczky ZB. Metabolic risk factors in patients with renal stones in KwaZulu Natal: an inter-racial study (Asian and Whites). BJU Int 2004;93:120–3
   PubMed Web of Science ®Google Scholar
• Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest 2005;115:2598–608
   Google Scholar
• Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs 2004;64:245–75
   PubMed Web of Science ®Google Scholar
• Jaeger P. Genetic versus environmental factors in renal stone disease. Curr Opin Nephrol Hypertens 1996;5:342–6
   PubMedGoogle Scholar
• Khan AS, Rai ME, Gandapur et al. Epidemiological risk factors and composition of urinary stones in Riyadh Saudi Arabia. J Ayub Med Coll Abbottabad 2004;16:56–8
   PubMedGoogle Scholar
• Maloney ME, Springhart WP, Ekeruo WO, et al. Ethnic background has minimal impact on the etiology of nephrolithiasis. J Urol 2005;173:2001–4
   PubMed Web of Science ®Google Scholar
• Moe OW. Kidney stones: pathophysiology and medical management. Lancet 2006;367:333–44
   PubMed Web of Science ®Google Scholar
• Parmar MS. Kidney stones. BMJ 2004;328:1420–4
   PubMed Web of Science ®Google Scholar
• Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005;293:455–62
   Google Scholar
• Reiss WG, Oles KS. Acetazolamide in the treatment of seizures. Ann Pharmacother 1996;30:514–9
   PubMed Web of Science ®Google Scholar
• Resor SR, Resor LD. Chronic acetazolamide monotherapy in the treatment of myoclonic epilepsy. Neurology 1990;40:1677–81
   PubMed Web of Science ®Google Scholar
• Kass MA, Kolker AE, Gordon M, et al. Acetazolamide and urolithiasis. Ophthalmology 1981;88:261–5
   PubMed Web of Science ®Google Scholar
• Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000;41(Suppl 1):S66–S71
   Google Scholar
• Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000;41(Suppl 1):S35–S39
   Google Scholar
• de Simone G, Di Fiore A, Menchise V, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett 2005;15:2315–20
   Google Scholar
• Lamb EJ, Stevens PE, Nashef L. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem 2004;41:166–9
   PubMedGoogle Scholar
• Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure 2004;13(Suppl 1):S59–S65
   PubMedGoogle Scholar
• Baulac M. Introduction to zonisamide. Epilepsy Res 2006;68\(Suppl. 2):S3–S9
   Google Scholar
• Macdonald RL. Zonisamide. Mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 867–72
   Google Scholar
• Masuda Y, Noguchi H, Karasawa T. Evidence against a significant implication of carbonic anhydrase inhibitory activity of zonisamide in its anticonvulsive effects. Arzneim-Forsch 1994;44:267–9
   Google Scholar
• Masuda Y, Karasawa T. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneim-Forsch 1993;43:416–7
   PubMed Web of Science ®Google Scholar
• Faught E, Ayala R, Montouris G, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57:1774–9
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46:1–11
   Google Scholar
• Sackellares JC, Ramsay RE, Wilder BJ, et al. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004;45:610–7
   PubMed Web of Science ®Google Scholar
• Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993;15:67–73
   PubMed Web of Science ®Google Scholar
• Leppik IE, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993;14:165–73
   PubMed Web of Science ®Google Scholar
• Kubota M, Nishi-Nagase M, Sakakihara Y, et al. Zonisamide-induced urinary lithiasis in patients with intractable epilepsy. Brain Dev 2000;22:230–3
   PubMed Web of Science ®Google Scholar
• Hasegawa H. Zonisamide adjunct therapy for elderly intractable seizure in VA outpatient clinic. Epilepsia 2003;44(Suppl 9):17 [abstract 1.038]
   Google Scholar
• Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37(Suppl 2):S18–S22
   PubMedGoogle Scholar
• Jonas R, Desai SS, Wu JY, et al. Topiramate, zonisamide, and the ketogenic diet: incidence of nephrolithiasis. Epilepsia 2002;43(Suppl 7):59 [abstract 1.161]
   Google Scholar
• Vazquez B, Ghacibeh G, Hopkins M, Devinsky O. Zonisamide and topiramate combination therapy: safety and tolerability. Epilepsia 2001;42(Suppl 7):261 [abstract 3.137]
   Google Scholar
• Rosenfeld WE. Safety and tolerability of zonisamide used concurrently with topiramate. Epilepsia 2001;42\(Suppl. 7 ):260 [abstract 3.131]
   Google Scholar
• Richards KC, Smith MC, Verma A. Continued use of zonisamide following development of renal calculi. Neurology 2005;64:763–4
   Google Scholar